Omadacycline

• Women of childbearing age living with active male partners must check their pregnancy status before initiating omadacycline therapy. Omadacycline can cause permanent teeth discoloration , enamel hypoplasia (thin or deficient enamel formation), and decreased bone growth in unborn babies. • Breastfeeding mothers who are treated with omadacycline should be advised not to breastfeed their babies during the treatment and wait for at least four days from the last dose to re-start. • Patients given omadacycline should be carefully observed for symptoms and signs of Clostridium difficile associated diarrhea (CDAD) such as watery or bloody stools with or without stomach pain and fever. • If CDAD is suspected or confirmed discontinue the treatment with omadacycline and provide proper medical attention with fluid or electrolyte management, protein supplements, and antibacterial medications for treating Clostridium infection. • In severe cases of CDAD, an opinion with a surgeon for a surgical evaluation should also be sought. • Monitoring for symptoms and signs of increased pressure in the brain, kidney or liver damage, pancreatitis is necessary during omadacycline therapy. Discontinue the treatment permanently if such serious side effects occur and treat the patients appropriately with proper medical care. • Patients should be strictly advised to avoid or minimize the exposure to direct sunlight, tanning beds, and treatment with Ultraviolet A or B (UV A/B) radiations. Patients moving outdoors must wear protective clothing and should apply sunscreen with the highest sun protection factor (SPF) to avoid sunburn. • Older patients with one or more additional diseases must be carefully monitored as there is a high risk of death while treating with omadacycline.